초록

본 연구는 한의학에서 가장 다용하는 치료요법 중의 하나인 간접구요법이 임상적으로는 효능 및 효과가 인정됨에도 불구하고 이에 대한 과학적근거가 거의 전무함으로 건강인을 대상으로 한 1차년도 이어서 2차 년도 엔 무작위, 단일 맹검, 대조군 비교 임상시험을 통해서 간접구 치료법의 항피로 효과의 과학적 검증과 항산화스트레스 관련된 기전을 밝혀졌음.

Abstract ▼

I.Purpose and necessity
Indirect moxibustion is one of main therapeutics in traditional Korean Medicine. Moxibustion is believed to be multi-effectiveand has been applied to patients for long clinical experience. However, insufficient evidence is a main issue to restrict to go to the world. This

I.Purpose and necessity
Indirect moxibustion is one of main therapeutics in traditional Korean Medicine. Moxibustion is believed to be multi-effectiveand has been applied to patients for long clinical experience. However, insufficient evidence is a main issue to restrict to go to the world. This project aimed to produce basis of scientific data for indirect moxibustion in aspects of clinical effects and its mechanisms in normal and fatigued people.
II.Contents of research
A. 1st year:A random,single blind and control clinical study using healthy volunteers
1) Measuring the SF36 score for QOL change
2) Measuring immune-related change in peripheral bloodlymphocytessubpopulation
3) Measuring peripheral blood 42 cytokines (ENA-78,GCSF,GM-CSF,GRO,GRO-α,I-309,IL-1 α , I L - 1 β , I L - 2 , I L - 3 , I L - 4 , I L - 5 , I L - 6 , I L - 1 0 , I L - 1 2 , p 4 0 , p 7 0 , I L - 1 3 , I L - 1 5 , I F N - α,MCP-1,MCP-2,MCP-3,MCSF,MDC,MIG,MIP-15,RANTES,SCF,SDF-1,TARC,TGF-β1,TNF- α,TNF-β,EDF,IGF-I,angigenin,oncostatin M,thrombopoietin,VEGF,PDGFBB,andleptin)
4) Safety-related data (CBC, LFT, U/A).
5) Serum oxidative stress/anti-oxidant biomakers (MDA, SOD, GSH,ROS,TEAC)
B. 2nd year: A random,single blind and control clinical study for chronic fatigue patients
1) Measuring the anti-fatigue effect using Chalder fatigue scale
2) Measuring the SF36 score for QOL change
3) Measuring immune-related change in peripheral blood lymphocytes subpopulation
4) Measuring peripheral blood 42 cytokines (ENA-78,GCSF,GM-CSF,GRO,GRO-α,I-309,IL-1 α , I L - 1 β , I L - 2 , I L - 3 , I L - 4 , I L - 5 , I L - 6 , I L - 1 0 , I L - 1 2 , p 4 0 , p 7 0 , I L - 1 3 , I L - 1 5 , I F N - α,MCP-1,MCP-2,MCP-3,MCSF,MDC,MIG,MIP-15,RANTES,SCF,SDF-1,TARC,TGF-β1,TNF- α,TNF-β,EDF,IGF I, angigenin, oncostatin M, thrombopoietin, VEGF, PDGF-BB, and leptin)
5) Safety-related data (CBC, LFT, U/A).
6) Serum oxidative stress/anti-oxidant biomakers (MDA, SOD, GSH,ROS,TEAC)
III.Results
1) The result produced a scientifically basic data (safety-related data such as CBC, LFT, U/A)
2) Immunological data after indirectmoxibustion (CV4,CV8) were produced (peripheral blood lymphocytes subpopulation and peripheral blood 42 cytokines)
3) Indirect moxibustion (CV4,CV8) showed anti-fatigue effect chronic fatigue patients.
4) Indirect moxibustion (CV4,CV8) showed positive effect on serum ROS,MDA and TAC levels, and also significantly improved the serum catalase activity.
IV.Application of the results
1) As a scientifically essential data, this result will be used for moxibustion-derived therapeutic development in future.
2) Provide an important scientific evidence on traditional indirect moxibustion.
3) These research using systemic, immunological and antioxidative method can applicate as mechanical research model for other traditional therapies in future.

목차 Contents

• 표지 ...1
• 제출문 ...4
• 보고서 요약서 ...5
• 요약문 ...6
• SUMMARY ...8
• 연구 성과 실적 및 향후 계획 ...10
• 참여연구원 현황표 ...16
• II. 총괄연구과제 연구결과 ...17
• 1. 연구개발과제의 배경 및 필요성 ...18
• 2. 국내외 기술개발 현황 ...18
• 3. 연구개발과제의 추진체계 ...21
• 4. 연구개발수행 내용 및 결과 ...22
• 5. 목표달성도 및 관련분야 기여도 ...42
• 6. 향후 연구성과 추진 계획 ...42
• 7. 연구개발결과의 파급효과 ...43
• 8. 연구개발결과의 활용계획 ...43
• 9. 연구개발과정에서 수집한 해외과학기술정보 ...43
• 10. 참고문헌 ...46
• III. 첨부서류 ...49
• 목차 ...50
• 1. 자체평가의견서 ...51
• 2. 실적 증빙자료 ...55